345 related articles for article (PubMed ID: 25537444)
21. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
[TBL] [Abstract][Full Text] [Related]
22. p53 status identifies triple-negative breast cancer patients who do not respond to adjuvant chemotherapy.
Coradini D; Biganzoli E; Ardoino I; Ambrogi F; Boracchi P; Demicheli R; Daidone MG; Moliterni A
Breast; 2015 Jun; 24(3):294-7. PubMed ID: 25698149
[TBL] [Abstract][Full Text] [Related]
23. Gene expression profiling to predict the risk of locoregional recurrence in breast cancer: a pooled analysis.
Drukker CA; Elias SG; Nijenhuis MV; Wesseling J; Bartelink H; Elkhuizen P; Fowble B; Whitworth PW; Patel RR; de Snoo FA; van 't Veer LJ; Beitsch PD; Rutgers EJ
Breast Cancer Res Treat; 2014 Dec; 148(3):599-613. PubMed ID: 25414025
[TBL] [Abstract][Full Text] [Related]
24. Prognostication of a 13-immune-related-gene signature in patients with early triple-negative breast cancer.
Kim JY; Jung HH; Sohn I; Woo SY; Cho H; Cho EY; Lee JE; Kim SW; Nam SJ; Park YH; Ahn JS; Im YH
Breast Cancer Res Treat; 2020 Nov; 184(2):325-334. PubMed ID: 32812178
[TBL] [Abstract][Full Text] [Related]
25. Elevated expression of HABP1 is a novel prognostic indicator in triple-negative breast cancers.
Wang J; Song Y; Liu T; Shi Q; Zhong Z; Wei W; Huang S; Pang D
Tumour Biol; 2015 Jun; 36(6):4793-9. PubMed ID: 25794640
[TBL] [Abstract][Full Text] [Related]
26. Breast-conserving therapy for triple-negative breast cancer.
Gangi A; Chung A; Mirocha J; Liou DZ; Leong T; Giuliano AE
JAMA Surg; 2014 Mar; 149(3):252-8. PubMed ID: 24382582
[TBL] [Abstract][Full Text] [Related]
27. Clinical activity of adjuvant cytokine-induced killer cell immunotherapy in patients with post-mastectomy triple-negative breast cancer.
Pan K; Guan XX; Li YQ; Zhao JJ; Li JJ; Qiu HJ; Weng DS; Wang QJ; Liu Q; Huang LX; He J; Chen SP; Ke ML; Zeng YX; Xia JC
Clin Cancer Res; 2014 Jun; 20(11):3003-11. PubMed ID: 24668644
[TBL] [Abstract][Full Text] [Related]
28. Identification of patients with node-negative, triple-negative breast cancer who benefit from adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy.
Wu CE; Chen SC; Lin YC; Lo YF; Hsueh S; Chang HK
Anticancer Res; 2014 Mar; 34(3):1301-6. PubMed ID: 24596377
[TBL] [Abstract][Full Text] [Related]
29. Integration of whole-genome sequencing and functional screening identifies a prognostic signature for lung metastasis in triple-negative breast cancer.
Xie G; Yang H; Ma D; Sun Y; Chen H; Hu X; Jiang YZ; Shao ZM
Int J Cancer; 2019 Nov; 145(10):2850-2860. PubMed ID: 30977117
[TBL] [Abstract][Full Text] [Related]
30. Prognostic relevance of biological subtype overrides that of TNM staging in breast cancer: discordance between stage and biology.
Jung HA; Park YH; Kim M; Kim S; Chang WJ; Choi MK; Hong JY; Kim SW; Kil WH; Lee JE; Nam SJ; Ahn JS; Im YH
Tumour Biol; 2015 Feb; 36(2):1073-9. PubMed ID: 25326808
[TBL] [Abstract][Full Text] [Related]
31. Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings.
Abdel-Fatah TM; Perry C; Dickinson P; Ball G; Moseley P; Madhusudan S; Ellis IO; Chan SY
Ann Oncol; 2013 Nov; 24(11):2801-7. PubMed ID: 23908177
[TBL] [Abstract][Full Text] [Related]
32. Oncologic safety of breast-conserving surgery compared to mastectomy in patients receiving neoadjuvant chemotherapy for locally advanced breast cancer.
Cho JH; Park JM; Park HS; Park S; Kim SI; Park BW
J Surg Oncol; 2013 Dec; 108(8):531-6. PubMed ID: 24115142
[TBL] [Abstract][Full Text] [Related]
33. A seven-Gene Signature assay improves prognostic risk stratification of perioperative chemotherapy treated gastroesophageal cancer patients from the MAGIC trial.
Smyth EC; Nyamundanda G; Cunningham D; Fontana E; Ragulan C; Tan IB; Lin SJ; Wotherspoon A; Nankivell M; Fassan M; Lampis A; Hahne JC; Davies AR; Lagergren J; Gossage JA; Maisey N; Green M; Zylstra JL; Allum WH; Langley RE; Tan P; Valeri N; Sadanandam A
Ann Oncol; 2018 Dec; 29(12):2356-2362. PubMed ID: 30481267
[TBL] [Abstract][Full Text] [Related]
34. CYPOR is a novel and independent prognostic biomarker of recurrence-free survival in triple-negative breast cancer patients.
Pedersen MH; Hood BL; Ehmsen S; Beck HC; Conrads TP; Bak M; Ditzel HJ; Leth-Larsen R
Int J Cancer; 2019 Feb; 144(3):631-640. PubMed ID: 30110125
[TBL] [Abstract][Full Text] [Related]
35. Safety and efficacy of pegylated liposomal doxorubicin-based adjuvant chemotherapy in patients with stage I-III triple-negative breast cancer.
Lien MY; Liu LC; Wang HC; Yeh MH; Chen CJ; Yeh SP; Bai LY; Liao YM; Lin CY; Hsieh CY; Lin CC; Li LY; Lin PH; Chiu CF
Anticancer Res; 2014 Dec; 34(12):7319-26. PubMed ID: 25503167
[TBL] [Abstract][Full Text] [Related]
36. A 3q gene signature associated with triple negative breast cancer organ specific metastasis and response to neoadjuvant chemotherapy.
Qian J; Chen H; Ji X; Eisenberg R; Chakravarthy AB; Mayer IA; Massion PP
Sci Rep; 2017 Apr; 7():45828. PubMed ID: 28387221
[TBL] [Abstract][Full Text] [Related]
37.
Uzelac B; Krivokuca A; Susnjar S; Milovanovic Z; Supic G
Genet Test Mol Biomarkers; 2021 Mar; 25(3):227-235. PubMed ID: 33734898
[No Abstract] [Full Text] [Related]
38. PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patients.
Absmaier M; Napieralski R; Schuster T; Aubele M; Walch A; Magdolen V; Dorn J; Gross E; Harbeck N; Noske A; Kiechle M; Schmitt M
Int J Oncol; 2018 Mar; 52(3):755-767. PubMed ID: 29328369
[TBL] [Abstract][Full Text] [Related]
39. Clinical relevance of the deregulated kallikrein-related peptidase 8 mRNA expression in breast cancer: a novel independent indicator of disease-free survival.
Michaelidou K; Ardavanis A; Scorilas A
Breast Cancer Res Treat; 2015 Jul; 152(2):323-36. PubMed ID: 26099606
[TBL] [Abstract][Full Text] [Related]
40. Analysis of Risk of Recurrence by Subtype in ≤ 1-cm Breast Tumors.
Colonna SV; Higgins AK; Alvarez J; Saville BR; Lawrence J; Abramson VG
Clin Breast Cancer; 2016 Jun; 16(3):223-31. PubMed ID: 26683741
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
